Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pretomanid

FDA-approved product (tablet, oral), marketed as Pretomanid.

Registered studies
49
Lab records
57
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pretomanid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Drug-resistant tuberculosis
  • Multidrug-resistant tuberculosis
  • Pulmonary tuberculosis
  • Tuberculosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for treatment of tuberculosis
FDA pharmacologic class
Antimycobacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J04AK08; FDA class Antimycobacterial

Repurposing investigation

Pretomanid is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

  • M. tuberculosis: measured active in 52 of 57 lab records
Open Pretomanid in ChEMBL Registered studies below
Show the 57 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pretomanid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

    NCT00567840 · start 2007-08

    Registered record
    Registry ID
    NCT00567840
    Conditions
    Pulmonary Tuberculosis
    Interventions
    PA-824
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-08
    Completion
    2007-12
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionPA-824
    PhasePhase 2
    Registry statusCompleted

  • Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects

    NCT01828827 · start 2007-03

    Registered record
    Registry ID
    NCT01828827
    Conditions
    Tuberculosis
    Interventions
    PA-824 1000 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-03
    Completion
    2007-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPA-824 1000 mg
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

    NCT03202693 · start 2006-03

    Registered record
    Registry ID
    NCT03202693
    Conditions
    Tuberculosis
    Interventions
    PA-824
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-03
    Completion
    2006-05
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPA-824
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted